• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Understanding COVID-19 Treatment Options

By: StatePoint Media
November 23, 2021 at 01:00 AM EST

photo

SPONSORED CONTENT -- (StatePoint) As COVID-19 restrictions are lifted, people are taking fewer precautions and the virus continues to spread in communities across the country. While getting vaccinated is the best way to prevent COVID-19, it’s also important to understand the potential treatment options available if you do get sick, particularly if you’re at high-risk for developing serious illness and complications.

As part of its mission to help prevent infection and severe illness from COVID-19, the American Lung Association has partnered with Regeneron Pharmaceuticals and GlaxoSmithKline to raise awareness about available treatment options. Here’s what to know:

Timing is Important

If you experience symptoms of COVID-19, it’s critical to get tested right away. If you’re a high-risk individual and test positive for COVID-19, speak to your healthcare provider about available treatment options that may help prevent severe illness and reduce the risk of hospitalization. Treatments, which include monoclonal antibodies (MABs), need to start as soon as possible and within 10 days of symptom onset to help prevent possible progression of severe illness.

Monoclonal Antibodies

MABs products that are authorized for emergency use by the Food and Drug Administration are used for patients who test positive for COVID-19, who are over 12 years old, are experiencing mild to moderate COVID-19 symptoms and who are at high risk of hospitalization. MABs are laboratory-made proteins that work by attaching to the replicating virus within an infected individual, which may enable the immune system to better recognize and stop the infection, preventing further illness from occurring. MAB treatment is given as an intravenous (IV) infusion or injection at a doctor’s office or outpatient center.

MAB Eligibility

It’s important to know whether you’re a higher-risk individual and eligible for MAB treatment. You’re considered high-risk if you’re aged 65 and older, have a chronic lung disease (including asthma, COPD, interstitial lung disease, cystic fibrosis or pulmonary hypertension) and if you have certain medical conditions. These conditions include being pregnant, overweight, or immunocompromised, as well as heart disease, diabetes, chronic kidney disease, sickle cell disease and neurodevelopmental disorders.

Treatments are widely available, and advocates say that efforts should be made to ensure that the communities most affected by COVID-19 have equitable access, this includes racial and ethnic minority groups, including Black, Latino/Hispanic and American Indian/Alaska Native communities.

If you do receive MABs, you should delay COVID-19 vaccination by at least 90 days.

For more information about COVID-19 and available treatments, visit lung.org.

Treatment options for COVID-19 are a step in the right direction to helping end this pandemic, say doctors, however it’s always preferable to prevent a disease than to treat it. Getting fully vaccinated against COVID-19 can help keep you from getting sick or spreading the infection to others.

*****

Photo Credit: (c) Digital Vision. / iStock via Getty Images Plus

More News

View More
MP Materials' New Role as a Strategic U.S. Asset
Today 14:22 EDT
Via MarketBeat
Topics Economy Government
Tickers AAPL MP
3 Healthcare Companies Insiders Are Buying
Today 14:09 EDT
Via MarketBeat
Topics Initial Public Offering
Tickers CAMP LLY SI
Analyst Downgrades Hit Homebuilders—But Opportunity Looms
Today 13:33 EDT
Via MarketBeat
Topics World Trade
Tickers LEN PHM
3 Defensive Stocks to Buy as Economic Uncertainty Lingers
Today 12:04 EDT
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CLX COST CVX
3 Dividend Hikes That Signal Renewed Strength in 2025
Today 11:34 EDT
Via MarketBeat
Topics Economy
Tickers ACN F GE GM HON THO
Recent Quotes
View More
Symbol Price Change (%)
GOOG  247.16
+2.52 (1.03%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap